TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02958553

Intervention type: DEVICE
Group type: OTHER
Intervention: Subject's own passive prosthesis
Description: Devices will vary. Data gathered will form a baseline.
Study: NCT02941744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: low fixed dose ipilimumab in combination with nivolumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: low fixed dose ipilimumab in combination with nivolumab
Study: NCT03438565

Intervention type: DEVICE
Intervention: Asahi Chikai Black 18 neurovascular guidewire
Description: The Asahi Chikai Black 18 microguidewire employs a reverse tapered shaft with 0.018 tip and 0.014 proximal shaft, which provides additional support and tactile feedback.
Study: NCT02345551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
Study: NCT04661774

Intervention type: OTHER
Group type: OTHER
Intervention: reflexology massage
Description: reflexology massage of the foot zone implicated in diaphragm stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: reflexology massage
Description: reflexology massage of the foot zone implicated in diaphragm stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: sham massage
Description: traditional massage of the foot

Intervention type: OTHER
Group type: OTHER
Intervention: sham massage
Description: traditional massage of the foot
Study: NCT04336709

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcipex II
Description: Water based intracanal medicament

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metapex
Description: Oil based intracanal medicament
Study: NCT00224835

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction Class
Description: Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiac Education Class
Description: Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format.
Study: NCT04929509

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-assembling peptide
Description: each Curodont Repair applicator unit contains both Curolox technology for guided enamel regeneration and water for activation of the device, each box contains 10 applicators

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nanosilver fluoride varnish
Description: The synthesis of aqueous solution of silver nanoparticles will be carried out via the chemical reduction of silver nitrate (1 mL, 0.11 M) with sodium borohydride (0.3 mL, 0.8 M) and chitosan biopolymer (28.7 mL, 2.5 mg/mL) as a stabilizing agent. Sodium fluoride (10,147 ppm of fluorine) will be incorporated at the end of the experiment.
Study: NCT01719003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg bid
Description: Metformin 1000 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin low dose qd
Description: Empagliflozin low dose once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high dose qd
Description: Empagliflozin high dose once daily
Study: NCT03816059

Intervention type: DIAGNOSTIC_TEST
Intervention: Respiratory virus testing
Description: All patients will be tested for respiratory viruses
Study: NCT01719003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin low dose bid
Description: Empagliflozin low dose split twice daily
Study: NCT00697151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 325 mg once a day; placebo warfarin once a day
Study: NCT01386255

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Baclofen
Description: The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
Study: NCT01719003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg bid
Description: Metformin 500 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high dose bid
Description: Empagliflozin high dose split twice daily
Study: NCT01386255

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo. No other names
Study: NCT03766607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (8 mg/kg loading dose; 6 mg/kg maintenance) administered intravenously every 21 days
Study: NCT03766607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab 8 mg/kg administered intravenously on days 1 and 15 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
Study: NCT03043404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement
Description: TAVR with Lotus Valve Flex System
Study: NCT02681835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC laryngoscope
Description: Intubation performed using C-MAC laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC laryngoscope
Description: Intubation performed using C-MAC laryngoscope
Study: NCT01719003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg bid
Description: Metformin 1000 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg bid
Description: Metformin 500 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg bid
Description: Metformin 1000 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high dose bid
Description: Empagliflozin high dose split twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg bid
Description: Metformin 1000 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin high dose bid
Description: Empagliflozin high dose split twice daily
Study: NCT01260025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEDylated Recombinant Human Endostatin
Description: The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
Study: NCT02532712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 Soft-capsule (500mg/1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 Soft-capsule (500mg/1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 Soft-capsule (500mg/1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 Soft-capsule (500mg/1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 Soft-capsule (500mg/1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 Soft-capsule (500mg/1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 Soft-capsule (500mg/1 capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EC-18
Description: EC-18 Soft-capsule (500mg/1 capsule)
Study: NCT04929509

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sodium fluoride varnish
Description: 5% sodium fluoride varnish; One ml of fluoride varnish contains 50 mg of sodium fluoride in an alcohol-based suspension of resins.
Study: NCT02681835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC laryngoscope
Description: Intubation performed using C-MAC laryngoscope
Study: NCT00986869

Intervention type: PROCEDURE
Intervention: Doppler echocardiogram
Description: All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
Study: NCT02681835

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: Intubation performed using laryngoscope with Macintosh blade

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: Intubation performed using laryngoscope with Macintosh blade

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh laryngoscope
Description: Intubation performed using laryngoscope with Macintosh blade
Study: NCT02532712

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same shape and size

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same shape and size

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same shape and size

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same shape and size

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same shape and size

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same shape and size

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same shape and size
Study: NCT01466387

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vi Polysaccharide Vaccine
Description: One dose of typhoid Vi polysaccharide vaccine.
Study: NCT00861874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20 mg/m2 IV, Days 1-5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
Study: NCT01947491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD01 Spray

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comp01 Lotion
Study: NCT01466387

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Typhoid Vi Polysaccharide Vaccine
Description: One dose of typhoid Vi polysaccharide vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever Vaccine
Description: One dose of yellow fever vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Yellow Fever Vaccine
Description: One dose of yellow fever vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis Vaccine
Description: Two doses of Japanese Encephalitis Vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Japanese Encephalitis Vaccine
Description: Two doses of Japanese Encephalitis Vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: Three doses of Rabies vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: Three doses of Rabies vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies Vaccine
Description: Three doses of Rabies vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-CRM Vaccine
Description: One dose of MenACWY-CRM vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-CRM Vaccine
Description: One dose of MenACWY-CRM vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-CRM Vaccine
Description: One dose of MenACWY-CRM vaccine.
Study: NCT02749812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Constant Continuous Positive Airway Pressure

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automatic continuous Positive Airway Pressure
Study: NCT02225756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Oral administration for a short time of cyclosporine A dose 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: Oral administration for a short time of cyclosporine A dose 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration for a short time of placebo
Study: NCT03552614

Intervention type: DEVICE
Intervention: Upper limb robot-assisted rehabilitation
Description: Upper limb robot-assisted rehabilitation is performed with Armeo®Spring. It is a passive exoskeleton with five degrees of freedom that guarantees passive arm weight support with springs.~The treatment was composed by 45 minutes of robotic training (5 times a week for 4 weeks) during which patients performed a customized pull of exergames.

Intervention type: OTHER
Intervention: physiotherapy
Description: Patients undergo 45-minute treatment sessions 5 times a week for 4 weeks of physiotherapy, focused on gross and fine motor ability to promote independence in daily activities, and it is customized on patients' need.
Study: NCT00996385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade (bortezomib) plus Eloxatin (oxaliplatin)
Description: One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
Study: NCT03943004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP-14927
Description: DFP-14927 is a large 4-arm-PEGylated-DFP-10917 molecule. DFP-10917 is a nucleoside analog similar to deoxycytidine.
Study: NCT04197999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1359
Description: Injection 10 mg/mL
Study: NCT03735186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 60 min treadmill exercise performed at 60% of maximum oxygen uptake.
Study: NCT02412826

Intervention type: DEVICE
Intervention: Abstats sensor
Description: The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
Study: NCT03445780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Description: Skin cooling with ethyl chloride spray 5 seconds prior to injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Description: Skin cooling with ethyl chloride spray 5 seconds prior to injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pinching
Description: Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pinching
Description: Skin between the distal palmar crease and the palmo digital crease will be pinched for 5 seconds prior to injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Site of Procedure
Description: Subjects will sit behind a screen with a small opening large enough to introduce the injected hand. They will not see any of the procedure
Study: NCT04166136

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transition from the Rearfoot to the Forefoot and Midfoot
Description: Participants in this group will perform a training aimed at the transition of foot strike pattern from the rearfoot to the forefoot and midfoot progressively. Initially a ten-minute race will be held at a comfortable warm-up speed. Then the participants in this group will run continuously at the usual treadmill speed for thirty minutes in a 12-week progressive training program. Participants will run shod and barefoot alternately. Each week the barefoot running time increased to 30 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Treatment Group
Description: This group will perform standard physiotherapeutic treatment performed at the Naval School. This treatment consists of the application of conventional TENS whose parameters are: alternating current, rectangular pulse, pulse duration 100μs, frequency of 100Hz for 12000 seconds. Laser therapy with an energy of 5 J at each point, irradiation area of 1cm², irradiation time of 20 seconds, 30 repetitions and total time of 6000 seconds.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Strengthening Group
Description: The participants of this group will perform muscle strengthening exercises for trunk and lower limbs divided into four phases of three weeks each. The total period of the program strength will be 12 weeks. Elastos® elastic bands of weak, medium and strong intensity will be used to provide progression to the exercises. The exercises will be supervised and supervised by two physiotherapists. A Phase 1 will consist of four exercises; a phase 2, phase 3 and phase 4 will consist of five different exercises each one. In addition to the muscle strengthening le strengthening protocol, this group will have free access to the standard physiotherapeutic treatment performed at the Naval School during and after the study.
Study: NCT00193856

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin Acetate
Description: LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin Acetate
Description: LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin Acetate
Description: LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin Acetate
Description: LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic Acid
Description: Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid
Description: Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional external beam therapy
Description: The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Conventional external beam therapy
Description: The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.
Study: NCT03512873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: Subjects will be treated with tranilast
Study: NCT03717012

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: stable dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: stable dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Description: 12 weeks
Study: NCT03838900

Intervention type: DEVICE
Intervention: Loop
Description: The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.

Intervention type: DEVICE
Intervention: Loop
Description: The Loop System consists of an insulin pump (certain versions of Medtronic insulin pumps) and a Dexcom or Medtronic CGM. The system includes an iPhone with the Loop app and a RileyLink to communicate between the pump and iPhone. An Apple Watch may optionally be used with the system.
Study: NCT03254264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Start Denver Model
Description: ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).~Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 'as-usual' intervention
Description: a control group receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
Study: NCT02671929

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: self-help program
Description: Access to the internet-based self-help program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-help program
Description: Access to the internet-based self-help program
Study: NCT02532712

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo with same shape and size
Study: NCT00436254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pNGVL3-hICD vaccine
Description: Plasmid-based DNA vaccine, given intradermally
Study: NCT00193856

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional external beam therapy
Description: The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Conventional external beam therapy
Description: The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with \>= 6 MV photons.
Study: NCT04013633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifesaver virtual reality training
Description: CPR training using the Lifesaver virtual reality application

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face training
Description: Short face-to-face CPR training
Study: NCT00436254

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sargramostim
Description: Given intradermally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunologic technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Undergo ELIspot (correlative studies)

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: protein expression analysis
Description: Undergo ELISA (correlative studies)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Undergo punch biopsy (correlative studies)